Buy1 小时
Cancer drugs help drive fourth-quarter sales beat at AstraZeneca
(Alliance News) - AstraZeneca PLC on Thursday ended a strong year with better-than-expected fourth quarter earnings and said its pipeline would support further growth in 2025.
AstraZeneca’s Q4 revenue jumps on strong Oncology and Cardiovascular drug sales
In addition to revenue growth, AstraZeneca's core earnings per share climbed 44% to $2.09. Research and development spending ...